Search

Ear Portal: An ENT and Audiology referral portal for improving access to ear health services for children using telehealth

Chris Deborah Peter Tanisha Greta Karina Brennan-Jones Lehmann Richmond Cayley Bernabei Tao PhD AO, MBBS, MSc MBBS MRCP(UK) FRACP BBiomed (Hons) BSc

Koorlungkas yarning: Exploring the impact of OM on early language and communication skills in urban Aboriginal families

Deborah Peter Lehmann Richmond AO, MBBS, MSc MBBS MRCP(UK) FRACP Honorary Emeritus Fellow Head, Vaccine Trials Group Honorary Emeritus Fellow Head,

Clinical Associate Professor Deborah Lehmann

Honorary Emeritus Fellow

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

“You’re telling us to go first?!” COVID-19 pandemic and vaccination experiences among Aboriginal adults in Western Australia

Globally, Indigenous populations have been disproportionately impacted by pandemics. In Australia, though national infection rates with COVID-19 infections in Aboriginal and/or Torres Strait Islander people were lower in the first 12 months of the COVID-19 pandemic, there was soon a greater burden in Aboriginal and/or Torres Strait Island people once Omicron was circulating. Uptake of the COVID-19 vaccine was also lower among Aboriginal and/or Torres Strait Islander people.

Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.

Clinical predictors of hypoxic pneumonia in children from the Eastern Highlands Province, Papua New Guinea: secondary analysis of two prospective observational studies

Pneumonia is the leading cause of death in young children globally and is prevalent in the Papua New Guinea highlands. We investigated clinical predictors of hypoxic pneumonia to inform local treatment guidelines in this resource-limited setting.

BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial)

BCG vaccination modulates immune responses to unrelated pathogens. This off-target effect could reduce the impact of emerging pathogens. As a readily available, inexpensive intervention that has a well-established safety profile, BCG is a good candidate for protecting healthcare workers (HCWs) and other vulnerable groups against COVID-19.

Reducing the Impact of Tinnitus on Children and Adolescents' Lives: A Mixed-Methods Concept Mapping Study

To generate a conceptual framework describing what is done to reduce the impact of chronic tinnitus on the lives of children and adolescents.

Funding boost music to the ears of WA children

A $6 million commitment from Wesfarmers to Telethon will fund vital research to reduce the impact of chronic ear infections and other serious diseases.